Literature DB >> 36258708

Novel Treatment of Ventilator Dyssynchrony From Central Alveolar Hypoventilation Syndrome Utilizing Scheduled 5-Hydroxytryptamine-3 Receptor Antagonist.

Aldin Malkoc1, Ashley Stading1, Stephanie Wong1, Tara Weaver1, Leslie Ghisletta1.   

Abstract

Traumatic brain injury (TBI) occurs in a large percentage of surgical trauma patients and is one of the leading causes of death amongst young teens and adults. Furthermore, individuals with TBIs often require mechanical ventilation and admission to the intensive care unit. As a result of their TBIs, these patients can develop central alveolar hypoventilation (CAH) secondary to disruptions in neuromodulatory respiratory brainstem control and neural signal initiation and integration. Prior studies have primarily focused their attention on treatment of congenital disorders of CAH, and limited research is available on intubated trauma patients who have signs of ventilator dyssynchrony. Current case reports and animal studies have suggested that noradrenergic and specific serotonergic medications are able to target specific neurologic pathways in the respiratory circuit and induce ventilator synchrony. This case series describes the clinical course of TBI patients treated for ventilator dyssynchrony secondary to CAH with a daily scheduled 5-hydroxytryptamine-3 (5-HT3) receptor antagonist. All patients were ultimately extubated and discharged from the hospital. Copyright 2022, Malkoc et al.

Entities:  

Keywords:  Central alveolar hypoventilation; Ondansetron; Traumatic brain injury; Ventilator

Year:  2022        PMID: 36258708      PMCID: PMC9534192          DOI: 10.14740/jmc3983

Source DB:  PubMed          Journal:  J Med Cases        ISSN: 1923-4155


  23 in total

1.  Ventilatory management and weaning in a patient with central hypoventilation caused by a brainstem cavernoma.

Authors:  G S U Rao; V J Ramesh; R K Lalla
Journal:  Acta Anaesthesiol Scand       Date:  2005-09       Impact factor: 2.105

2.  Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat.

Authors:  D W Carley; M Radulovacki
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

3.  Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.

Authors:  Geoffrey Ginter; Abdulghani Sankari; Mehdi Eshraghi; Harold Obiakor; Hossein Yarandi; Susmita Chowdhuri; Anan Salloum; M Safwan Badr
Journal:  J Appl Physiol (1985)       Date:  2020-02-20

Review 4.  Brainstem respiratory networks: building blocks and microcircuits.

Authors:  Jeffrey C Smith; Ana P L Abdala; Anke Borgmann; Ilya A Rybak; Julian F R Paton
Journal:  Trends Neurosci       Date:  2012-12-17       Impact factor: 13.837

5.  Activation of mouse bronchopulmonary C-fibres by serotonin and allergen-ovalbumin challenge.

Authors:  Carl Potenzieri; Sonya Meeker; Bradley J Undem
Journal:  J Physiol       Date:  2012-08-20       Impact factor: 5.182

Review 6.  Abnormalities of respiratory control and the respiratory motor unit.

Authors:  Martín A Nogués; Eduardo Benarroch
Journal:  Neurologist       Date:  2008-09       Impact factor: 1.398

Review 7.  Neural Control of Breathing and CO2 Homeostasis.

Authors:  Patrice G Guyenet; Douglas A Bayliss
Journal:  Neuron       Date:  2015-09-02       Impact factor: 17.173

8.  Pharmacological characterization of 5-hydroxytryptamine-induced apnea in the rat.

Authors:  M Yoshioka; Y Goda; H Togashi; M Matsumoto; H Saito
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

9.  Early tracheostomy in severe traumatic brain injury: evidence for decreased mechanical ventilation and increased hospital mortality.

Authors:  C Michael Dunham; Anthony F Cutrona; Brian S Gruber; Javier E Calderon; Kenneth J Ransom; Laurie L Flowers
Journal:  Int J Burns Trauma       Date:  2014-02-22

10.  High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions.

Authors:  Emily R Stern; Rebbia Shahab; Stephanie J Grimaldi; Evan Leibu; James W Murrough; Lazar Fleysher; Michael K Parides; Barbara J Coffey; Katherine E Burdick; Wayne K Goodman
Journal:  Neuropsychopharmacology       Date:  2018-08-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.